Panitumumab (Vectibix)
Customize your policy alerts
Sign up for Aetna Policy 0748 alerts
Get alerted when Policy 0748 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity, precertification, and coverage criteria for panitumumab (Vectibix) in commercial Aetna medical plans, primarily addressing use in colorectal cancer and related testing requirements.
No material clinical or coverage changes in this revision.
Coverage Criteria for Panitumumab (Vectibix)
Initial Approval — CRC
Covered when ONE of the following two alternative pathways is met and member has not previously experienced clinical failure on cetuximab:
Applies to unresectable/inoperable, advanced, or metastatic disease including appendiceal and anal adenocarcinoma
Alternative biomarker-driven combination pathway
Continuation of Therapy
Covered when ALL of the following are met:
Requesting reauthorization
Biomarker-driven coverage and tumor-specific evidence
Evidence-supported use is generally limited to patients with RAS wild-type tumors and appropriate clinical indications.
Amado et al (2008) and Freeman et al (2008) showed confinement of benefit to wild-type KRAS tumors.
Some trials showed benefit in KRAS wild-type biliary tract disease while others did not; SBA/AAC trial stopped for futility.
Breast cancer (neoadjuvant, inflammatory / triple-negative subgroups)
Evidence from phase II studies suggests possible benefit in biologically selected subgroups:
Further randomized data pending; consider enrollment in trials or biomarker-defined use.
Cutaneous squamous cell carcinoma (locally advanced / unresectable)
Phase II and case-series evidence:
Results are early and require validation; consider as option when local therapy is not suitable and after discussion of limited evidence.
Esophageal / gastro-esophageal adenocarcinoma
Randomized data do not support adding panitumumab to standard first-line chemotherapy in unselected populations:
Biomarker-selected use not established.
Metastatic colorectal cancer (re-challenge / continuous EGFR therapy)
Evidence on panitumumab beyond progression and continuous use is mixed and biomarker-dependent:
Prior authorization should document molecular testing results and prior anti‑EGFR exposure.
Head and neck squamous cell carcinoma (locally advanced)
Randomized trials comparing addition or substitution of panitumumab in chemoradiotherapy regimens:
Panitumumab cannot replace cisplatin with radiotherapy; role needs reassessment.
Glioma / ErbB targeting
Biologic rationale but limited clinical efficacy to date:
Evidence primarily preclinical/early‑phase; not established for routine use.
Coverage with criteria and restrictions
Coverage recommendations and criteria inferred from the document:
Explicit exclusion for KRAS‑mutant CRC in document.
Supported by phase II/III trials.
Supported by randomized/phase II trial findings.
Derived from phase I/II data in pancreatic, sarcoma, and other cancers.
Coverage for colorectal cancer (general)
Covered when ALL of the following are met:
Derived from trial descriptions and prescribing information
CAIRO5 subgroup coverage stance
Restrictive consideration for first-line induction in initially unresectable CRC liver metastases:
Reflects CAIRO5 conclusions
Administration and toxicity management
Safety and administration conditions:
Per labeling recommendations
Aetna considers panitumumab (Vectibix) experimental and investigational for multiple non-colorectal cancer indications and for specific drug combinations where effectiveness has not been established. Examples of tumor types listed as experimental include ampullary adenocarcinoma, biliary tract cancer, bladder cancer, breast cancer, cutaneous squamous cell carcinoma, esophageal and gastric cancers, glioma, head and neck cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, penile cancer, and sarcoma.
In addition, Aetna identifies certain investigational panitumumab constructs and combinations (for example, 212Pb-panitumumab, panitumumab-DOTA-111In radioimmunotherapy, and combinations with bevacizumab, erlotinib, or gefitinib) as experimental because clinical benefit has not been established and these uses are not supported by sufficient evidence.
Panitumumab (Vectibix) should not be used in patients with known hypersensitivity to panitumumab or any component of the product. The safety and effectiveness of panitumumab in pediatric and adolescent patients have not been established and thus use in these populations is excluded unless evidence supports otherwise.
The prescribing and coverage guidance also note contraindications or limitations related to pregnancy and breastfeeding without an appropriate documented risk–benefit discussion and require that labeled safety considerations be followed when evaluating requests for therapy.
Randomized trial evidence does not support adding panitumumab to certain first-line gastro‑esophageal chemotherapy regimens in unselected patients. In particular, trial data showed that adding panitumumab to EOC/EOC‑type regimens did not improve overall survival and was associated with increased gastrointestinal and dermatologic toxicity; therefore, panitumumab added to first-line EOC/ECX/mFOLFOX6 chemotherapy for unselected advanced esophago‑gastric or gastro‑esophageal adenocarcinoma is not recommended and is considered excluded in this setting.
More generally, Aetna designates the addition of panitumumab to standard first‑line chemotherapy for unselected gastro‑esophageal adenocarcinoma as not medically necessary based on the randomized data showing no benefit and higher toxicity.
Use of panitumumab in colorectal cancer with KRAS (or broader RAS) activating mutations is explicitly excluded. Multiple sources in the policy state that patients with KRAS‑mutant tumors do not benefit from anti‑EGFR monoclonal antibodies and that provision of panitumumab in this population is contraindicated.
The FDA‑labeled indication for panitumumab and the policy both require demonstration of RAS (KRAS and NRAS) wild‑type status for use in metastatic colorectal cancer; requests for therapy in tumors with documented activating KRAS mutations will be denied.
Concurrent administration of panitumumab with certain other targeted agents is prohibited per the policy. Specifically, panitumumab may not be used in conjunction with cetuximab (Erbitux), erlotinib (Tarceva), gefitinib (Iressa), or bevacizumab (Avastin) because combinations with these agents are either not studied, ineffective, or associated with worse outcomes in clinical trials (for example, PACCE results with bevacizumab).
Requests for coverage that propose concomitant use of panitumumab with these agents should be denied or require an investigational review as described in the policy.
The policy reiterates that use of panitumumab in colorectal cancer patients with KRAS mutations is excluded because activating KRAS mutations are associated with lack of response to EGFR inhibitors and may be associated with worse outcomes.
Prior to authorization for colorectal cancer, documentation of KRAS/RAS wild‑type status is required; panitumumab is not indicated for RAS‑mutant or unknown RAS status per the Vectibix limitation of use.
The policy prohibits concurrent use of panitumumab with other EGFR‑directed monoclonal antibodies or with certain targeted agents. Specifically, panitumumab should not be used with cetuximab (Erbitux), erlotinib (Tarceva), gefitinib (Iressa), or bevacizumab (Avastin) because these combinations are either unestablished or contraindicated based on trial data.
Providers requesting panitumumab in combination with any of these agents must provide supportive clinical trial evidence and obtain investigational review; absent compelling justification, such combinations are considered noncovered.
This Clinical Policy Bulletin provides a summary of the plan’s medical necessity criteria for panitumumab and related administrative requirements, but it contains only a partial, general description of plan or program benefits and does not constitute a contract.
Participating providers are responsible for clinical decision‑making and must follow plan procedures for prior authorization and documentation; the bulletin may be updated and plan‑specific provisions apply.
Panitumumab (Vectibix) is indicated and covered only for patients with metastatic colorectal cancer whose tumors are RAS (KRAS and NRAS) wild‑type. The policy explicitly states that panitumumab is not indicated for patients with RAS‑mutant or unknown RAS status, consistent with the labeled limitation of use.
For colorectal cancer indications, prior authorization must include documentation of the tumor’s RAS/KRAS wild‑type status to support coverage decisions; absence of this documentation or presence of activating RAS mutations precludes approval.
Clinical trial and regulatory evidence show that tumors with activating KRAS mutations do not respond to panitumumab and therefore panitumumab use in this setting is considered inappropriate. Amado and others demonstrated confinement of benefit to KRAS/RAS wild‑type tumors.
As a result, the policy requires molecular testing demonstrating absence of activating KRAS (and extended RAS) mutations before panitumumab is considered medically necessary for colorectal cancer.
Randomized phase II/III trials in unselected metastatic gastro‑esophageal adenocarcinoma populations found no survival benefit and increased toxicity when panitumumab was added to standard first‑line chemotherapy. Therefore, panitumumab added to standard first‑line chemotherapy in unselected metastatic gastro‑esophageal adenocarcinoma is not medically necessary and will not meet coverage criteria.
These findings support exclusion of panitumumab in this unselected first‑line gastric/gastro‑esophageal setting unless biomarker‑selected benefit is subsequently demonstrated.
Multiple randomized and controlled trials in non‑small cell lung cancer and in combined chemoradiation settings did not demonstrate benefit from adding panitumumab and in some studies showed increased toxicity and higher mortality. As such, use of panitumumab in NSCLC (either combined with standard chemotherapy or as part of chemoradiation) is not medically necessary outside of clinical trials.
Trial closures for futility and higher adverse event rates underscore that panitumumab should not be used routinely in NSCLC.
In the CAIRO5 randomized study of first‑line induction regimens for initially unresectable colorectal cancer liver metastases, addition of panitumumab to FOLFOX or FOLFIRI in left‑sided, RAS/BRAFV600E wild‑type tumors did not improve outcomes versus bevacizumab and was associated with higher toxicity. Therefore, addition of panitumumab to FOLFOX or FOLFIRI for left‑sided, RAS/BRAFV600E wild‑type unresectable CRC liver metastases is not preferred and is not supported for routine use in place of bevacizumab.
CAIRO5 subgroup findings favor bevacizumab‑containing regimens in many settings and indicate that panitumumab‑containing regimens had more adverse events in these comparisons.
Related CPT and HCPCS codes are referenced under the coverage criteria and in the CODING section of the policy. Providers should refer to the CODING section for the full list of relevant procedure and drug billing codes (for example, CPT code 81275 for KRAS testing and HCPCS code J9303 for panitumumab billing).
Accurate documentation of the indicated ICD‑10 diagnosis code consistent with policy criteria (for example, left‑sided colon malignancy codes when coverage criteria specify laterality) is required when submitting prior authorization requests.
Coding and Billing
| 81275 | KRAS gene analysis; variants in exon 2 (eg, codons 12 and 13). |
| 81276 | additional variant(s) (eg, codon 61, codon 146). |
| 81311 | NRAS gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61). |
| 81404 | Molecular pathology procedure, Level 5. |
| 81210 | BRAF V600 variant analysis. |
| 88363 | Examination and selection of retrieved archival tissue(s) for molecular analysis. |
| 96365-96368 | Intravenous infusion, for therapy, prophylaxis, or diagnosis. |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular. |
| 96379 | Unlisted therapeutic intravenous or intra-arterial injection or infusion. |
| 96413-96417 | Chemotherapy administration, intravenous infusion technique. |
| C18.0-C18.9 | Malignant neoplasm of colon [covered for left-sided tumors only]. |
| C19-C21.8 | Malignant neoplasm of rectosigmoid junction, rectum, anus and anal canal. |
| C15.3-C15.9 | Malignant neoplasm of esophagus (listed as not covered for CPB indications). |
| C16.0-C16.9 | Malignant neoplasm of stomach (listed as not covered for CPB indications). |
| C44.02 | Squamous cell carcinoma of skin. |
| C50.011-C50.929 | Malignant neoplasm of breast. |
| HCPCS: J9306 | Panitumumab injection (per 1 mg) (listed as example for panitumumab billing in prior auth guidance). |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab 6 mg/kg IV every 14 days | ||
| Metastatic colorectal cancer — as first‑line in combination with FOLFOX, or as monotherapy after progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimens | ||
| Covered with criteria (RAS [KRAS/NRAS] wild-type required; prior clinical failure on cetuximab disallows coverage; dosing per labeling: 6 mg/kg q14d) |
Provider Actions, Authorization, and Documentation
Precertification Required
Precertification/authorization is required for panitumumab (Vectibix). Lack of precertification may result in denial. For precertification call (866) 752-7021 or fax (888) 267-3277; Statement of Medical Necessity (SMN) forms are available via Aetna Specialty Pharmacy Precertification.
- Precertification required for all Aetna participating providers and members in applicable plan designs.
- Failure to precertify may lead to claim denial.
Prior Authorization May Be Required
Prior authorization may be required per plan provisions; providers should consult the Clinical Policy Bulletin and plan-specific rules when submitting requests.
- Authorization determinations follow plan benefits and the Clinical Policy Bulletin.
- Providers must verify plan-specific prior authorization requirements before treatment.
Prior Authorization and Required Documentation
Prior authorization requests must include documentation of tumor diagnosis, line of therapy, prior therapies (including platinum exposure for HNSCC when applicable), and relevant biomarker testing. CPT codes for molecular testing (e.g., KRAS, NRAS, BRAF) should be documented on requests.
KRAS/RAS Wild-Type Documentation Required; Mutation Exclusion
Requests for panitumumab for colorectal cancer must include evidence of RAS (KRAS and NRAS) wild-type status (or documented alternative authorized molecular scenario per criteria). Use in tumors with activating KRAS/RAS mutations lacks efficacy and may be denied.
- KRAS/RAS wild-type verification is required to support panitumumab efficacy in mCRC.
- Requests for patients with KRAS or other RAS activating mutations should be denied unless meeting an explicit authorized exception in the policy.
- If BRAF V600E is present, documentation that panitumumab will be used in combination with encorafenib is required per criteria.
KRAS Mutation Exclusion and Concomitant Therapy Restrictions
Panitumumab should not be used in patients with KRAS-mutated colorectal cancer; such use is contraindicated due to lack of response and possible worse outcomes. Panitumumab may not be used in conjunction with cetuximab, erlotinib, gefitinib, or bevacizumab based on trial data.
- Use in colorectal cancer patients with KRAS mutations will be denied.
- Concurrent use with cetuximab (Erbitux), erlotinib (Tarceva), gefitinib (Iressa), or bevacizumab (Avastin) is not allowed.
REAL3/PACCE and Other Negative Trial Implications
Clinical trial data (e.g., PACCE, REAL3, EOC studies) have shown lack of benefit or harm when panitumumab (or EGFR antibodies) were added to certain chemotherapy regimens in unselected populations; cite these outcomes when denying requests lacking appropriate biomarker selection.
- PACCE and REAL3/REAL3-like trials showed decreased PFS or no OS benefit and increased toxicity when EGFR antibodies were added in unselected populations.
- Addition of panitumumab to EOC chemotherapy did not improve OS and increased grade 3–4 toxicities; therefore not recommended for unselected gastro-esophageal adenocarcinoma.
- CAIRO5 results: in left-sided, RAS/BRAFV600E wild-type tumors, panitumumab added to FOLFOX/FOLFIRI showed no clinical benefit over bevacizumab and increased toxicity in some groups.
Prior Anti‑EGFR Exposure, Re‑challenge, and Use After Cetuximab Intolerance
Re-challenge or use after prior anti-EGFR exposure requires careful documentation. Prior clinical failure on cetuximab is a contraindication to panitumumab per the policy; however, limited case reports suggest panitumumab may be used after cetuximab hypersensitivity/intolerance in select cases under strict observation and with appropriate authorization.
- Requests should state whether the member previously experienced clinical failure on cetuximab — prior clinical failure disallows panitumumab.
- For cetuximab hypersensitivity/intolerance (not clinical failure), include detailed clinical rationale and prior reaction documentation; single-patient reports exist but are not definitive evidence of safety or efficacy.
- Re-challenge strategies and liquid biopsy (ctDNA) results that show RAS wild-type status may be considered in authorization decisions; provide serial molecular testing results when applicable.
Molecular Testing and Tumor Location Documentation
When applicable, provide molecular testing documentation including tumor RAS and BRAF V600E status and primary tumor laterality (left vs right) for colorectal cancer, and whether testing was performed on tissue or liquid biopsy (circulating tumor DNA).
- Specify testing method and date (tissue vs liquid biopsy) and include laboratory reports.
- Document primary tumor laterality (left-sided vs right-sided) for colon cancer, as this affects regimen selection and authorization.
- If liquid biopsy is used to guide re-challenge or later-line therapy, include serial ctDNA results showing RAS/BRAF status.
Required Clinical Documentation
Clinical documentation should include diagnosis, tumor type and stage, prior therapies (with dates), line of therapy, biomarker results, and clinical rationale for panitumumab use in context of available evidence and guideline-supported sequencing (for example CAIRO5 subgroup considerations).
- Include complete prior therapy history (agents, dates, responses) and objective evidence of progression or intolerance when relevant.
- Provide clinical rationale referencing guideline- or trial-based sequencing (e.g., preferred regimens vary by mutation status and sidedness in CAIRO5).
- Attach pathology and molecular test reports to the authorization request.
Provider Responsibility and Policy Nature
Participating providers are independent contractors and are solely responsible for medical advice and treatment. The Clinical Policy Bulletin is a partial description of plan benefits, may be updated, and does not constitute a contract.
- Policy contents may change; providers should confirm current criteria and plan provisions.
- Clinical policy guidance does not replace professional judgment — treating providers remain responsible for patient care.
Background and Evidence Summary
Panitumumab (Vectibix) is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR) and is indicated for treatment of metastatic colorectal cancer that is RAS (KRAS and NRAS) wild‑type.
The FDA‑approved dosing regimen referenced in the policy and trials is 6 mg/kg IV every 14 days, and the policy’s coverage criteria align with this labeled/trial dosing for first‑line combination with FOLFOX or as monotherapy in later‑line settings after progression on prior chemotherapies.
Definitions and Biomarker Terms
Line of Therapy Considerations
first-line | second-line
See prescribing information for labeled indications and limits.
first-line
Evidence from Jensen and Hezel phase II trials.
second-line
Use following cetuximab intolerance described in small case series; prior clinical failure on cetuximab is disallowed for coverage.
second-line | re-challenge
BEYOND and other small studies investigated P‑FOLFIRI beyond progression.
first-line
Not recommended in unselected first‑line use.
second-line | alternative for cisplatin-ineligible definitive therapy
Evidence from single‑arm phase II trials; safety signals present.
first-line investigational/combined-modality
Phase I/II trials showed unacceptable toxicity in some regimens.
first-line
Not preferred versus bevacizumab in left‑sided RAS/BRAF WT subgroup.
salvage
Supported by phase III and earlier trials (Amado et al., prescribing information).
Biomarker Requirements for Coverage
Covered and Investigational Regimens
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab 6 mg/kg IV every 14 days | ||
| Metastatic colorectal cancer — first‑line with FOLFOX or as monotherapy after progression on standard chemotherapies | ||
| Covered with criteria (requires documented RAS [KRAS/NRAS] wild-type status; limitation of use: not indicated for RAS‑mutant or unknown RAS status) |
| Regimen | Agents/Context | Coverage |
|---|---|---|
| Panitumumab in combination | ||
| Bevacizumab, erlotinib, or gefitinib (any combination) — combinations not established | ||
| Experimental / investigational (effectiveness not established) |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab combined with gemcitabine + oxaliplatin (± capecitabine) — panitumumab 6 mg/kg q2w used in trials | ||
| KRAS wild-type biliary tract cancer — first‑line trial regimens | ||
| Mixed / supportive for further study; marker‑driven (KRAS wild‑type) selection used in trials — considered investigational outside trial or without KRAS WT documentation |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab combined with anthracycline‑taxane–based neoadjuvant chemotherapy (e.g., panitumumab + FEC100 → docetaxel; panitumumab + nab‑paclitaxel + carboplatin → FEC) | ||
| Neoadjuvant therapy in breast cancer — triple‑negative and inflammatory breast cancer (TNBC/IBC) evaluated in phase II trials | ||
| Investigational / experimental — signal of pCR in selected subgroups (e.g., TN IBC) but not established for routine coverage |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab added to MMC‑5‑FU–based chemoradiation (as studied: panitumumab 3 mg/kg with MMC/5‑FU and IMRT) | ||
| Locally advanced anal squamous cell carcinoma (combined with definitive CRT) — phase II trial | ||
| Not covered / not recommended — trial failed to meet expected CR rate and showed poor tolerance |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab + FEC100 → docetaxel; or panitumumab + nab‑paclitaxel + carboplatin → FEC (neoadjuvant schemas used in IBC trials) | ||
| Inflammatory breast cancer / operable TNBC evaluated in neoadjuvant studies (pCR observed in subsets) | ||
| Investigational — promising pCR in subsets but requires randomized validation; considered experimental for routine coverage |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab 6 mg/kg IV every 2 weeks (single‑agent) as used in phase II CSCC trial | ||
| Advanced cutaneous squamous cell carcinoma not suitable for local therapy — phase II population | ||
| Experimental / limited evidence — single‑agent activity observed (ORR ~31%) in phase II; consider investigational or case‑by‑case with documentation |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab combined with FOLFIRI (continuous use or re‑challenge strategies) | ||
| Metastatic colorectal cancer — re‑challenge or beyond‑progression strategies selected by circulating tumor DNA (RAS/BRAF WT) | ||
| Mixed — potential benefit when selected by circulating tumor DNA (RAS/BRAF WT) but requires further validation; prior authorization should document molecular testing |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab added to EOC/ECX/mFOLFOX6 (e.g., panitumumab 6–9 mg/kg with various chemo backbones) | ||
| First‑line treatment for unselected advanced gastro‑esophageal adenocarcinoma | ||
| Not covered / not medically necessary — randomized trials showed no benefit and increased toxicity (REAL3 and other studies) |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab 9 mg/kg IV every 2–3 weeks in combination with radiotherapy ± chemotherapy (as studied in various trials) | ||
| Used with altered fractionation radiotherapy or with paclitaxel induction and bio‑RT in head & neck or other settings | ||
| Mixed / investigational — studied but not established as superior; safety concerns and increased toxicity reported in some trials |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab combined with pemetrexed/cisplatin or carboplatin/paclitaxel, or used to replace cisplatin in definitive chemoradiation regimens | ||
| Non‑small cell lung cancer or as cisplatin replacement in HNSCC definitive CRT (evaluated in trials) | ||
| Not covered / not recommended — trials showed lack of benefit and/or increased toxicity; replacement of cisplatin not established |
| Regimen | Indication | Coverage |
|---|---|---|
| Radiolabeled panitumumab constructs (e.g., panitumumab‑DOTA‑111In) under preclinical/early‑phase investigation | ||
| Theranostic applications and preclinical models for triple‑negative breast cancer and other targets | ||
| Experimental / investigational — preclinical and early‑phase evidence only; not covered for routine use |
| Regimen | Indication | Coverage |
|---|---|---|
| Panitumumab 6 mg/kg IV every 14 days combined with FOLFOX or FOLFIRI as evaluated in CAIRO5 | ||
| First‑line induction for initially unresectable colorectal cancer liver metastases (CAIRO5 subgroups) — used in left‑sided, RAS/BRAFV600E WT arm comparisons | ||
| Mixed / not preferred in specific subgroup — CAIRO5 showed no benefit and more toxicity versus bevacizumab in left‑sided RAS/BRAFV600E WT tumors; panitumumab not preferred in that subgroup (coverage contingent on subgroup and documentation) |
| Regimen | Indication | Coverage |
|---|---|---|
| Triplet: ganitumab + everolimus + panitumumab (phase I dose‑escalation) or doublet ganitumab + everolimus | ||
| Advanced sarcoma / refractory solid tumors evaluated in phase I trial | ||
| Triplet associated with unacceptable toxicity (not covered); doublet showed activity but remains investigational |
| Guidance | Action | Coverage implication |
|---|---|---|
| Infusion reaction management | ||
| Reduce infusion rate by 50% for mild reactions; terminate infusion for severe infusion reactions | ||
| Per labeling — informs withholding/termination decisions; see authorization documentation for discontinuation criteria |
| Regimen | Indication / Context | Coverage |
|---|---|---|
| Panitumumab (Vectibix) — anti‑EGFR monoclonal antibody | ||
| Referenced in literature and reviews on anti‑EGFR therapy for advanced colorectal cancer | ||
| Informational / referenced — supports contextual discussion of anti‑EGFR class; coverage determined by indication‑specific criteria |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.